Mary Wilson
Well-known member
Published: 30 December 2022
DOI https://doi.org/10.1038/s41541-022-00586-7
Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Lisa Tietze, Anette Kolderup, Aina Anthi, Marton König, Gro Nygaard, Andreas Lind, Fredrik Müller, Lise Sofie Nissen-Meyer, Per Magnus, Lill Trogstad, Siri Mjaaland, Arne Søraas, Karsten Midtvedt, Anders Åsberg, Andreas Barratt-Due, Asle W. Medhus, Marte Lie Høivk, Knut Lundin, Randi Fuglaas Karlsen, Reidun Dahle, …Fridtjof Lund-Johansen Show authors
Abstract
Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.
https://www.nature.com/articles/s41541-022-00586-7#citeas
DOI https://doi.org/10.1038/s41541-022-00586-7
Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Lisa Tietze, Anette Kolderup, Aina Anthi, Marton König, Gro Nygaard, Andreas Lind, Fredrik Müller, Lise Sofie Nissen-Meyer, Per Magnus, Lill Trogstad, Siri Mjaaland, Arne Søraas, Karsten Midtvedt, Anders Åsberg, Andreas Barratt-Due, Asle W. Medhus, Marte Lie Høivk, Knut Lundin, Randi Fuglaas Karlsen, Reidun Dahle, …Fridtjof Lund-Johansen Show authors
Abstract
Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.
https://www.nature.com/articles/s41541-022-00586-7#citeas